Koa B, Borja AJ, Aly M, Padmanabhan S, Tran J, Zhang V, Rojulpote C, Pierson SK, Tamakloe MA, Khor JS, Werner TJ, Fajgenbaum DC, Alavi A, Revheim ME. "Emerging role of 18F-FDG PET/CT in Castleman disease: a review." Insights Imaging. 2021 Mar 11;12(1):35. doi: 10.1186/s13244-021-00963-1. 

Zhang MY, Jia MN, Chen J, Feng J, Cao XX, Zhou DB, Fajgenbaum DC, Zhang L, Li J. "UCD with MCD-like inflammatory state: surgical excision is highly effective." Blood Adv. 2021 Jan 12;5(1):122-128. doi: 10.1182/bloodadvances.2020003607.

Kawano M, Hara S, Yachie A, Inoue D, Sato Y, Fajgenbaum DC. "HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease." Rheumatology (Oxford). 2021 Jan 5;60(1):e3-e4. doi: 10.1093/rheumatology/keaa362. 


Abdallah H, Porterfield F, Fajgenbaum D "Symptomatic relapse and long-term sequelae of COVID-19 in a previously healthy 30-year-old man." BMJ Case Reports CP 2020;13:e239825.

Fajgenbaum DC, Wu D, Goodman A, Wong R, Chadburn A, Nasta S, Srkalovic G, Mukherjee S, Leitch H, Jayanthan R, Ferrero S, Sato Y, Schey S, Dispenzieri A, Oksenhendler E, Zinzani PL, Lechowicz MJ, Hoffmann C, Pemmaraju N, Bagg A, Fossa A, Lim MS, van Rhee F; Castleman Disease Collaborative Network Scientific Advisory Board diagnostic criteria international working group and treatment guidelines international working group. "Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease." Am J Hematol. 2020 Dec;95(12):1553-1561. doi: 10.1002/ajh.25992. 

Fajgenbaum, David C. “A Longitudinal Population Level Analysis of Healthcare Resource Utilization, Comorbidity, and Survival in Idiopathic Multicentric Castleman Disease Patients.” Blood. 136.Supplement 1 (2020): 11–11. Web.

Fajgenbaum DC, Phillips AD. "Commentary on A Case of Rapid Deterioration with Marked Hypergammaglobulinemia." Clin Chem. 2020 Nov 1;66(11):1378-1379. doi: 10.1093/clinchem/hvaa156

Fajgenbaum DC, Rader DJ. "Teaching Old Drugs New Tricks: Statins for COVID-19?" Cell Metab. 2020 Aug 4;32(2):145-147. doi: 10.1016/j.cmet.2020.07.006. PMID: 32755604; PMCID: PMC7402379.

Fajgenbaum, D.C., Khor, J.S., Gorzewski, A. et al. "Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review." Infect Dis Ther (2020).

Pai RL, Japp AS, Gonzalez M, et al. "Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease." JCI Insight. 2020;5(9):135031.

Arenas DJ, Floess K, Kobrin D, et al. "Increased mTOR activation in idiopathic multicentric Castleman disease." Blood. 2020;blood.2019002792.

Dispenzieri A, Fajgenbaum DC. "Overview of Castleman disease." Blood. 2020;135(16):1353‐1364

Yoshimi A, Trippett TM, Zhang N, et al. "Genetic basis for iMCD-TAFRO." Oncogene. 2020;39(15):3218‐3225.

Bernabei L, Waxman A, Caponetti G, Fajgenbaum DC, Weiss BM. "AA amyloidosis associated with Castleman disease: A case report and review of the literature." Medicine (Baltimore). 2020;99(6):e18978.


Suarez, Alexander, Curran Reilly, and David C. Fajgenbaum. "Quantitative analysis of a rare disease network’s international contact database and E-repository provides insights into biobanking in the electronic consent era." Orphanet journal of rare diseases 14.1 (2019): 173.

Fajgenbaum, David C., et al. "Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease." The Journal of clinical investigation (2019).

Nabel, Christopher S., et al. "Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease." PloS one 14.6 (2019): e0218660.

Kobrin DM, Pinto AL, Parente ST, et al. "Letter to the editor regarding 'Non-cirrhotic portal hypertension associated with multicentric Castleman's disease: a case report'." Acta Oncol. 2019;58(4):515‐517.

Zhang, Lu, et al. "Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease." Blood 133.16 (2019): 1720-1728.

Zuccato, Mary, Dustin Shilling, and David C. Fajgenbaum. "The Collaborative Network Approach: a model for advancing patient-centric research for Castleman disease and other rare diseases." Emerging Topics in Life Sciences 3.1 (2019): 97-105.

Leurs, Amélie, et al. "Renal pathologic findings in TAFRO syndrome: Is there a continuum between thrombotic microangiopathy and membranoproliferative glomerulonephritis? A case report and literature review." Frontiers in Immunology 10 (2019): 1489.

Morra, Deanna E., et al. "Predictors of response to anti‐IL 6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data." British journal of haematology 184.2 (2019): 232-241. 


Fajgenbaum, David C. "Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease." Blood 132.22 (2018): 2323-2330.

Van Rhee, Frits, et al. "International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease." Blood 132.20 (2018): 2115-2124.

Dong Y, Zhang L, Nong L, et al. "Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease." Ann Hematol. 2018;97(9):1641‐1647.

Baker, Turner S., et al. "A novel FAS mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease." Blood advances 2.21 (2018): 2959.

Pierson SK, Stonestrom AJ, Shilling D, et al. "Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease." Am J Hematol. 2018;93(7):902‐912.

Lee, Jinmin, et al. "Perspective from the 5th international pemphigus and pemphigoid foundation scientific conference." Frontiers in medicine 5 (2018): 306.

Fajgenbaum DC, Shilling D. "Castleman Disease Pathogenesis." Hematol Oncol Clin North Am. 2018;32(1):11‐21.

Soudet, Simon, et al. "Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology." Current research in translational medicine 66.3 (2018): 83-86. 


Louis C, Vijgen S, Samii K, et al. "TAFRO Syndrome in Caucasians: A Case Report and Review of the Literature." Front Med (Lausanne). 2017;4:149. 

Srkalovic G, Marijanovic I, Srkalovic MB, Fajgenbaum DC. "TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease." Bosn J Basic Med Sci. 2017;17(2):81‐84.

Yu L, Tu M, Cortes J, et al. "Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease." Blood. 2017;129(12):1658‐1668.

Fajgenbaum DC, Uldrick TS, Bagg A, et al."International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease." Blood. 2017;129(12):1646‐1657.

Behnia F, Elojeimy S, Matesan M, Fajgenbaum DC. "Potential value of FDG PET-CT in diagnosis and follow-up of TAFRO syndrome." Ann Hematol. 2017;96(3):497‐500.


Liu AY, Nabel CS, Finkelman BS, et al. "Idiopathic multicentric Castleman's disease: a systematic literature review." Lancet Haematol. 2016;3(4):e163‐e175. 

Fajgenbaum DC, Ruth JR, Kelleher D, Rubenstein AH. "The collaborative network approach: a new framework to accelerate Castleman's disease and other rare disease research." Lancet Haematol. 2016;3(4):e150‐e152.

Iwaki N, Fajgenbaum DC, Nabel CS, et al. "Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease." Am J Hematol. 2016;91(2):220‐226.

Fajgenbaum DC, Kurzrock R. "Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease." Immunotherapy. 2016;8(1):17‐26.


Newman SK, Jayanthan RK, Mitchell GW, et al. "Taking Control of Castleman Disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease Research." Yale J Biol Med. 2015;88(4):383‐388. 


Fajgenbaum DC, van Rhee F, Nabel CS. "HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy." Blood. 2014;123(19):2924‐2933.

Fajgenbaum DC, Rosenbach M, van Rhee F, Nasir A, Reutter J. "Eruptive cherry hemangiomatosis associated with multicentric Castleman disease: a case report and diagnostic clue" [published correction appears in JAMA Dermatol. 2014 Apr;150(4):460. Fajgenbaum, David [corrected to Fajgenbaum, David C]]. JAMA Dermatol. 2013;149(2):204‐208.